Literature DB >> 1714449

Human acid beta-glucosidase. Use of inhibitory and activating monoclonal antibodies to investigate the enzyme's catalytic mechanism and saposin A and C binding sites.

D Fabbro1, G A Grabowski.   

Abstract

Of 14 identified epitopes on human GCase (acid beta-glucosidase), monoclonal antibodies (MCABs) recognizing 3 produced inhibition and 1 resulted in activation of GCase. MCABs F1 and F2 completely, and MCAB 61 partially (approximately 70%), inhibited GCase activity. Substrates and active site-directed inhibitors (specific sphingolipid and 5-amino-5-deoxyglucose derivatives) protected the enzyme from inhibition by MCAB F1 and F2, but not that by MCAB 61. Conduritol B epoxide did not protect GCase from the inhibition by these MCABs when covalently bound to the active site. These results indicated highly specific binding requirements of MCABs F1 and F2 for residues in a complex active site. In comparison, kinetic analyses using GCase transition state analogues, N-alkyl-glucosylamines, and MCAB 61 demonstrated that this MCAB "freezes" the conformation of the enzyme and inhibits GCase by preventing formation of a conformer needed for maximal catalytic rates. The activating MCAB 122 mimicked the effects of saposin C and competed with this natural activator for residues on the enzyme. Interaction of saposin A and saposin C or MCAB 122 with GCase produced a synergistic effect leading to a marked sensitization of the enzyme to these activators. No such synergism or additivity was found for the maximal catalytic rate since it could be achieved by saturating amounts of any one or combinations of these activators. In the presence of MCAB 61, only 15 to 25% of the maximal activation of GCase was obtained by saposin C or MCAB 122, indicating that the major activation effects of these effectors derived from an induction of a GCase conformational change. These results demonstrate that saposins A and C mediate their activating effects by binding to distinct sites on GCase. Furthermore, major components of the mechanisms for catalysis and saposin C activation are due to conformational changes during the transition state. These findings have implications for understanding the perturbations of GCase function due to the missense mutations which cause Gaucher disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1714449

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Mechanism of glucocerebrosidase activation and dysfunction in Gaucher disease unraveled by molecular dynamics and deep learning.

Authors:  Raquel Romero; Arvind Ramanathan; Tony Yuen; Debsindhu Bhowmik; Mehr Mathew; Lubna Bashir Munshi; Seher Javaid; Madison Bloch; Daria Lizneva; Alina Rahimova; Ayesha Khan; Charit Taneja; Se-Min Kim; Li Sun; Maria I New; Shozeb Haider; Mone Zaidi
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-26       Impact factor: 11.205

2.  A non-glycosylated and functionally deficient mutant (N215H) of the sphingolipid activator protein B (SAP-B) in a novel case of metachromatic leukodystrophy (MLD).

Authors:  D Wrobe; M Henseler; S Huettler; S I Pascual Pascual; A Chabas; K Sandhoff
Journal:  J Inherit Metab Dis       Date:  2000-02       Impact factor: 4.982

3.  Identification of the binding and activating sites of the sphingolipid activator protein, saposin C, with glucocerebrosidase.

Authors:  S Weiler; Y Kishimoto; J S O'Brien; J A Barranger; J M Tomich
Journal:  Protein Sci       Date:  1995-04       Impact factor: 6.725

4.  Metabolism of GM1 ganglioside in cultured skin fibroblasts: anomalies in gangliosidoses, sialidoses, and sphingolipid activator protein (SAP, saposin) 1 and prosaposin deficient disorders.

Authors:  B Schmid; B C Paton; K Sandhoff; K Harzer
Journal:  Hum Genet       Date:  1992-07       Impact factor: 4.132

5.  Additional biochemical findings in a patient and fetal sibling with a genetic defect in the sphingolipid activator protein (SAP) precursor, prosaposin. Evidence for a deficiency in SAP-1 and for a normal lysosomal neuraminidase.

Authors:  B C Paton; B Schmid; B Kustermann-Kuhn; A Poulos; K Harzer
Journal:  Biochem J       Date:  1992-07-15       Impact factor: 3.857

6.  Insights into Krabbe disease from structures of galactocerebrosidase.

Authors:  Janet E Deane; Stephen C Graham; Nee Na Kim; Penelope E Stein; Rosamund McNair; M Begoña Cachón-González; Timothy M Cox; Randy J Read
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-29       Impact factor: 11.205

Review 7.  Saposins and their interaction with lipids.

Authors:  A M Vaccaro; R Salvioli; M Tatti; F Ciaffoni
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

8.  Involvement of acid beta-glucosidase 1 in the salvage pathway of ceramide formation.

Authors:  Kazuyuki Kitatani; Kely Sheldon; Vinodh Rajagopalan; Viviana Anelli; Russell W Jenkins; Ying Sun; Gregory A Grabowski; Lina M Obeid; Yusuf A Hannun
Journal:  J Biol Chem       Date:  2009-03-11       Impact factor: 5.157

9.  Prosaposin deficiency: further characterization of the sphingolipid activator protein-deficient sibs. Multiple glycolipid elevations (including lactosylceramidosis), partial enzyme deficiencies and ultrastructure of the skin in this generalized sphingolipid storage disease.

Authors:  V Bradová; F Smíd; B Ulrich-Bott; W Roggendorf; B C Paton; K Harzer
Journal:  Hum Genet       Date:  1993-09       Impact factor: 4.132

10.  The LIMP-2/SCARB2 binding motif on acid β-glucosidase: basic and applied implications for Gaucher disease and associated neurodegenerative diseases.

Authors:  Benjamin Liou; Wendy D Haffey; Kenneth D Greis; Gregory A Grabowski
Journal:  J Biol Chem       Date:  2014-09-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.